Erasca, Inc. (ERAS)
ERAS Stock Price Chart
Explore Erasca, Inc. interactive price chart. Choose custom timeframes to analyze ERAS price movements and trends.
ERAS Company Profile
Discover essential business fundamentals and corporate details for Erasca, Inc. (ERAS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Jul 2021
Employees
103.00
Website
https://www.erasca.comCEO
Jonathan E. Lim
Description
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
ERAS Financial Timeline
Browse a chronological timeline of Erasca, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.12.
Earnings released on 11 May 2026
EPS came in at -$0.60 falling short of the estimated -$0.11 by -432.72%.
Earnings released on 12 Mar 2026
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%.
Earnings released on 12 Nov 2025
EPS came in at -$0.11 matching the estimated -$0.11.
Earnings released on 12 Aug 2025
EPS came in at -$0.12 matching the estimated -$0.12.
Earnings released on 13 May 2025
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 20 Mar 2025
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 12 Nov 2024
EPS came in at -$0.11 surpassing the estimated -$0.17 by +35.29%.
Earnings released on 12 Aug 2024
EPS came in at -$0.29 falling short of the estimated -$0.17 by -70.59%.
Earnings released on 8 May 2024
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%.
Earnings released on 27 Mar 2024
EPS came in at -$0.20 surpassing the estimated -$0.24 by +16.67%, while revenue for the quarter reached $5.58m .
Earnings released on 9 Nov 2023
EPS came in at -$0.20 surpassing the estimated -$0.21 by +4.76%.
Earnings released on 10 Aug 2023
EPS came in at -$0.21 surpassing the estimated -$0.27 by +22.22%.
Earnings released on 15 May 2023
EPS came in at -$0.22 surpassing the estimated -$0.30 by +26.67%.
Earnings released on 23 Mar 2023
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%.
Earnings released on 9 Nov 2022
EPS came in at -$0.29 surpassing the estimated -$0.31 by +6.45%.
Earnings released on 11 Aug 2022
EPS came in at -$0.30 surpassing the estimated -$0.34 by +11.76%.
Earnings released on 12 May 2022
EPS came in at -$0.31 falling short of the estimated -$0.30 by -3.33%.
Earnings released on 24 Mar 2022
EPS came in at -$0.26 surpassing the estimated -$0.31 by +16.13%.
Earnings released on 10 Nov 2021
EPS came in at -$0.27 surpassing the estimated -$0.32 by +15.62%.
Earnings released on 26 Aug 2021
EPS came in at -$1.20 falling short of the estimated -$0.65 by -84.62%.
ERAS Stock Performance
Access detailed ERAS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
